LaserOptek Secures ANVISA Approval in Brazil for Three Laser Devices

LaserOptek’s flagship products have received marketing authorization from Brazil’s National Health Surveillance Agency (ANVISA).

According to LaserOptek on November 5, it has completed Brazil ANVISA registration for three flagship laser devices: Helios III, Helios 785 Pico, and PicoLO PREMIUM. Brazil requires products to undergo individual registration procedures, but with its entire flagship lineup now authorized, the company can supply a portfolio of products rather than just a single device.

LaserOptek has also strengthened its distribution network by recently signing an exclusive partnership agreement with local company ENTERA. ENTERA has a sales network serving dermatology and plastic surgery clinics across Brazil, as well as a team of specialized sales professionals. It has also completed the recruitment of local professionals in Brazil in the fields of clinical support, service, and management.

Lee Changjin, CEO of LaserOptek, said, "With marketing authorization for our flagship products, distribution channels, and local support staff now in place, we are ready to fully launch our sales operations in the Brazilian market. Building on our localized sales and customer support system, we will develop Latin America into our second growth engine after North America and further strengthen our position in the global market."

This content was produced with the assistance of AI translation services.